Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice
Open accessThe DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index; 2 of the 8 sources its claims cite were checked for support.
Abstract
Background: Toxoplasma gondii is an apicomplexan parasite that affects the health of humans and livestock, and an effective vaccine is urgently required. Nanoparticles can modulate and improve cellular and humoral immune responses. Methods: In the current study, poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles were used as a delivery system for the T. gondii dense granule antigens GRA12 and GRA7. BALB/c mice were injected with the vaccines and protective efficacy was evaluated. Results: Mice immunized with PLGA+GRA12 exhibited significantly higher IgG, and a noticeable predominance of IgG2a over IgG1 was also observed. There was a 1.5-fold higher level of lymphocyte proliferation in PLGA+GRA12-injected mice compared to Alum+GRA12-immunized mice. Higher levels of IFN-g and IL-10 and a lower level of IL-4 were detected, indicating that Th1 and Th2 immune responses were induced but the predominant response was Th1. There were no significant differences between Alum+GRA7-immunized and PLGA+GRA7-immunized groups. Immunization with these four vaccines resulted in significantly reduced parasite loads, but they were lowest in PLGA+GRA12-immunized mice. The survival times of mice immunized with PLGA+GRA12 were also significantly longer than those of mice in the other vaccinated groups. Conclusion: The current study indicated that T. gondii GRA12 recombinant protein encapsulated in PLGA nanoparticles is a promising vaccine against acute toxoplasmosis, but PLGA is almost useless for enhancing the immune response induced by T. gondii GRA7 recombinant protein.
Overview
CoChat Summary
## TL;DR
This mouse study tested recombinant Toxoplasma gondii GRA12 or GRA7 proteins delivered in PLGA nanoparticles versus alum or controls. PLGA-encapsulated GRA12 performed best, inducing stronger immune responses, lower parasite burdens, and longer survival after acute RH strain challenge.
## Key findings
- PLGA+GRA12 induced the strongest antibody response, with significantly higher IgG than Alum+GRA12 and a predominance of IgG2a over IgG1; the paper reports IgG2a was higher than IgG1 in the PLGA+GRA12 group and that IgG2a was higher there than in all other vaccine groups.
- Lymphocyte proliferation in PLGA+GRA12 was about 1.54-fold higher than in Alum+GRA12.
- In splenocyte cultures, PLGA+GRA12 produced 2030.50 pg/mL IFN-γ, compared with 1133.14 pg/mL in Alum+GRA12; PLGA+GRA7 had 1219.44 pg/mL vs 898.31 pg/mL in Alum+GRA7, with no significant difference.
- After challenge, parasite loads were significantly reduced in all vaccinated groups, but PLGA+GRA12 was lowest; relative to Alum+GRA12, PLGA+GRA12 had parasite loads 3.08-fold lower in heart, 2.49-fold lower in liver, 3.16-fold lower in lung, and 6.30-fold lower in spleen.
- Survival after RH strain challenge was longest in PLGA+GRA12: mean survival time 14.5 days, versus 9.5 days for Alum+GRA12; control mice died by 4.5 days.
## Methods
- Experimental vaccine study in female BALB/c mice, aged 6–8 weeks, with 13 mice per group; eight groups included PLGA-NPs-GRA7, PLGA-NPs-GRA12, Alum-GRA7, Alum-GRA12, Alum alone, PLGA alone, PBS, and an unimmunized group.
- Recombinant GRA7 and GRA12 proteins were produced, encapsulated in PLGA nanoparticles using a water/oil/water solvent evaporation method, and characterized by TEM and dynamic light scattering; reported mean diameters were 106.0 ± 22.1 nm for PLGA+GRA12 and 130.8 ± 27.1 nm for PLGA+GRA7.
- Mice received three intraperitoneal immunizations at 14-day intervals; 5 weeks after the last immunization, subsets were tested for IgG/IgG1/IgG2a ELISA, splenocyte proliferation, cytokines (IFN-γ, IL-4, IL-10), qPCR parasite burden, and Kaplan–Meier survival after challenge with 1 × 10^3 RH tachyzoites.
## Limitations
- The authors explicitly note that one candidate antigen may induce only partial protective immunity, and that a combined vaccine including multiple parasite life stages may be needed for complete protection.
- They also state that it would be informative to evaluate PLGA+GRA12 in low-virulence T. gondii strains in future experiments.
- Evident from the text: the study assessed protection only in BALB/c mice against the acute RH strain challenge, so broader strain- or host-generalizability is not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
2 Valid · 0 Not valid · 3 Not checked · 51 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In recent years the protective effects of numerous T. gondii antigens have been evaluated, and the dense granule antigens (GRAs) are potential candidates for vaccines which may prevent T. gondii infection (Golkar et al., 2007; Hiszczyńska-Sawicka et al., 2011; Zheng et al., 2019).”
§ Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice > Introduction
What the sources say
- Not checked — no full text of the sourcecites Golkar et al., 2007 source
- Not checked — no full text of the sourcecites Hiszczyńska-Sawicka et al., 2011 source
- Supportedcites Zheng et al., 2019 source
The Introduction identifies GRA24 as a dense granule antigen and frames it as a possible vaccine target against T. gondii infection. The Discussion reports immune responses and prolonged survival in vaccinated, challenged mice, supporting the hedged claim of vaccine potential; it does not establish that infection was prevented. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“GRA12 is a key T. gondii virulence factor that resists host innate immunity triggered by IFN-γ (Fox et al., 2019).”
§ Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice > Introduction
What the sources say
- Supportedcites Fox et al., 2019 source
The Results section reports that deleting GRA12 reduced parasite virulence and survival in IFN-γ-activated host cells, while restoring GRA12 rescued those defects. It concludes that GRA12 enables the parasitophorous vacuole to resist host IFN-γ in both low- and high-virulence strains. Page numbers are not available in the supplied copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to mice in the PBS, Alum alone, and PLGA alone control groups, mice in the Alum+GRA7, PLGA+GRA7, Alum+GRA12, and PLGA+GRA12 groups exhibited significantly less parasites in the heart (p< 0.001), spleen (p< 0.001), lungs (p< 0.01), and liver (p< 0.01) (Figures 7A-D).”
§ Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice > Results > Parasite loads in mice
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alum+GRA12, PLGA+GRA12, Alum+GRA7, and PLGA+GRA7 induced significantly higher IgG1 and IgG2a titers than those of the PBS, Alum alone, and PLGA alone control groups (p< 0.001).”
§ Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice > Results > Antibody secretion in mice
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Splenocyte culture IL-4 was significantly higher in the Alum+GRA12 and PLGA+GRA12 groups compared to the control groups (p< 0.05) (Figure 6B).”
§ Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice > Results > Splenocyte cytokine production
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 56 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 4
- The quote only partly states this claim. 1
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
Der, S. D., Zhou, A., Williams, B. R. G., & Silverman, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15623 · Cited by 1,816
Dubey, J. P., Lindsay, D. S., & Speer, C. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.267 · Cited by 1,181
Toxoplasma gondii: transmission, diagnosis and prevention
Hill, D., & Dubey, J. P. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00485.x · Cited by 1,173
Interferon-γ: the Major Mediator of Resistance Against Toxoplasma gondii
Suzuki, Y., Orellana, M. A., Schreiber, R. D., & Remington, J. S. (1988) · Science · doi:10.1126/science.3128869 · Cited by 1,173
Modulation of innate immunity by Toxoplasma gondii virulence effectors
Hunter, C. A., & Sibley, L. D. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2858 · Cited by 570
Immune response and immunopathology during toxoplasmosis
Dupont, C. D., Christian, D. A., & Hunter, C. A. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0339-3 · Cited by 359
Jeffery, H., Davis, S. S., & O'Hagan, D. T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018980020506 · Cited by 355
A commercial vaccine for ovine toxoplasmosis
Buxton, D., & Innes, E. A. (1995) · Parasitology · doi:10.1017/s003118200000144x · Cited by 317
Cited by
Li, J., Yu, K., Wu, Z.-X., Yang, S., Tian, Y., Zhu, X.-Q., & Zheng, X.-N. (2024) · Parasites & Vectors · doi:10.1186/s13071-024-06461-9 · Cited by 15
Hosseininejad, Z., Daryani, A., Fasihi‐Ramandi, M., Asgarian‐Omran, H., Nayeri, T., Dodangeh, S., Amouei, A., Javidnia, J., Mayahi, S., Sarvi, S., et al. (2025) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2025.e00269 · Cited by 9
Hasan, T., Shimoda, N., Nakamura, S., Fox, B. A., Bzik, D. J., Ushio-Watanabe, N., & Nishikawa, Y. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.062 · Cited by 9
Lagunas‐Cortés, N., García-Sánchez, B. Y., Ríos‐Castro, E., Vega‐López, M. A., González‐Pozos, S., Díaz-Martín, R. D., Carranza, J. M., Ramírez‐Flores, C. J., & Mondragón‐Flores, R. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105454 · Cited by 5
Araujo-Ruiz, K., López-Flores, D. I., Martínez-Muné, M. K., García-Sánchez, B. Y., Ramírez‐Flores, C. J., Sandoval-Rodríguez, F. E., Ríos‐Castro, E., Mondragón-Castelán, M. E., González‐Pozos, S., & Mondragón‐Flores, R. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105509 · Cited by 3
Metadata
- Authors
- Sun, H.-C., Deng, P.-M., Fu, Y., Deng, J.-H., Xie, R.-H., Huang, J., Qi, M., & Shi, T.-Y.
- Affiliations
- Xinjiang Production and Construction Corps (CN)
- ZheJiang Academy of Agricultural Sciences (CN)
- Corresponding author
- Qi, Meng
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2023-07-12
- Volume
- 13
- Pages
- 1209755-1209755
- ISSN
- 2235-2988 (ISSN-L)
- PMC
- PMC10368986
- OpenAlex
- W4384023864
- Cited by
- 22
- References
- 61
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 8
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (31802183, 32072883)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Toxoplasma gondii, toxoplasmosis vaccine, PLGA nanoparticles, GRA7, recombinant protein vaccine, Th1 response, IgG2a, infection intensity, nanoparticle vaccine delivery
- MeSH terms
- Alum Compounds, Animals, Antibodies, Protozoan, Antigens, Protozoan, Humans, Mice, Inbred BALB C, Recombinant Proteins, Toxoplasma, Toxoplasmosis, Protozoan Proteins, Protozoan Vaccines, Lactic Acid, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice. https://app.cochat.ai/papers/10.3389/fcimb.2023.1209755
- The paper
- Sun, H.-C., Deng, P.-M., Fu, Y., Deng, J.-H., Xie, R.-H., Huang, J., Qi, M., & Shi, T.-Y. (2023). Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1209755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.